Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Amylyx is a debt-free, zero-revenue biotech pivot whose valuation now hinges on one pivotal avexitide Phase 3 readout.
Overview
Amylyx has transformed from an ALS commercial-stage company into a zero-revenue clinical-stage biotech after withdrawing Relyvrio/Albrioza and cutting 70% of its workforce. Its future now depends almost entirely on avexitide, a $35.1 million acquired Phase 3-ready GLP-1 receptor antagonist for post-bariatric hypoglycemia. With no approved PBH therapies, poor off-label alternatives, and an estimated 160,000 U.S. patients, avexitide could become a first-in-class commercial franchise—but the investment case is highly binary ahead of Q3 2026 Phase 3 LUCIDITY data.